Case Report: Chemoimmunotherapy in microsatellite-instability-high advanced goblet cell carcinoma of the colon

Case Report: Chemoimmunotherapy in microsatellite-instability-high advanced goblet cell carcinoma of the colon

BackgroundMismatch repair (MMR) deficiency is a fundamental factor affecting the management treatment outcomes of colorectal cancer (CRC). MMR status can be diagnosed by both immunohistochemistry (IHC) polymerase chain reaction (PCR). Since tumors with MMR deficiency are prone to respond to immunoth...

Full description

Bibliographic Details
Main Authors:	Arda Ulaş Mutlu, Erman Aytaç, Mehmet Gülmez, Sibel Erdamar, Leyla Özer
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-07-01
Series:	Frontiers in Immunology
Subjects:	chemoimmunotherapy metastatic colon cancer (mCRC) complete response MSI-H microsatellite unstable (high) goblet cell
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1160586/full

Similar Items

Instability of Non-Standard Microsatellites in Relation to Prognosis in Metastatic Colorectal Cancer Patients
by: Francesca Pirini, et al.
Published: (2020-05-01)

Skin Toxicity as a Predictor of Survival in Metastatic Colorectal Cancer Patients Treated with Anti-EGFR: Fact or Fallacy?
by: Ting-Yu Chiang, et al.
Published: (2023-03-01)

The Screening and COnsensus Based on Practices and Evidence (SCOPE) Program Results of a Survey on Daily Practice Patterns for Patients with Metastatic Colorectal Cancer—A Swiss Perspective in the Context of an International Viewpoint
by: Alexander R. Siebenhüner, et al.
Published: (2022-08-01)

Evaluation of microsatellite instability in routine examinations of surgical samples
by: Pawel Wlaszczuk, et al.
Published: (2022-01-01)

Microsatellite unstable colorectal cancers are associated with increased CD1a- and CD83-positive dendritic cell infiltration
by: Maya Gulubova, et al.
Published: (2023-12-01)

The Screening and COnsensus Based on Practices and Evidence (SCOPE) Program–Results of a Survey on Daily Practice Patterns for Patients with mCRC
by: Gerald Prager, et al.
Published: (2021-06-01)

Microsatellite instability: a review of what the oncologist should know
by: Kai Li, et al.
Published: (2020-01-01)

Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer
by: Chiara Cremolini, et al.
Published: (2023-02-01)

Fruquintinib in Combination With PD-1 Inhibitors in Patients With Refractory Non-MSI-H/pMMR Metastatic Colorectal Cancer: A Real-World Study in China
by: Miaomiao Gou, et al.
Published: (2022-07-01)

Safety, Feasibility and Technical Considerations from a Prospective, Observational Study—CIREL: Irinotecan-TACE for CRLM in 152 Patients
by: Thomas Helmberger, et al.
Published: (2022-10-01)

Role of Patient-Reported Outcomes in Clinical Trials in Metastatic Colorectal Cancer: A Scoping Review
by: Jan Gerard Maring, et al.
Published: (2023-02-01)

Single-cell sequencing reveals the immune microenvironment landscape related to anti-PD-1 resistance in metastatic colorectal cancer with high microsatellite instability
by: Tao Wu, et al.
Published: (2023-04-01)

Current Landscape and Potential Challenges of Immune Checkpoint Inhibitors in Microsatellite Stable Metastatic Colorectal Carcinoma
by: María San-Román-Gil, et al.
Published: (2023-01-01)

Predictive value of prognostic nutritional and systemic immune-inflammation indices for patients with microsatellite instability-high metastatic colorectal cancer receiving immunotherapy
by: Jiahong Yi, et al.
Published: (2023-05-01)

Clinicopathological Profiles Associated with Discordant <i>RAS</i> Mutational Status between Liquid and Tissue Biopsies in a Real-World Cohort of Metastatic Colorectal Cancer
by: Elena Brozos-Vázquez, et al.
Published: (2023-07-01)

Anlotinib combined with TAS-102 as the third-line treatment for a patient with metastatic colon cancer: A case report
by: Qizheng Li, et al.
Published: (2022-11-01)

Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients
by: Xiaojing Xu, et al.
Published: (2020-10-01)

Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review
by: J. Han van Krieken, et al.
Published: (2017-11-01)

Molecular and Computational Methods for the Detection of Microsatellite Instability in Cancer
by: Laura G. Baudrin, et al.
Published: (2018-12-01)

A novel NGS-based microsatellite instability (MSI) status classifier with 9 loci for colorectal cancer patients
by: Kai Zheng, et al.
Published: (2020-05-01)

Tas-102 for Refractory Metastatic Colorectal Cancer: A Multicenter Retrospective Cohort Study
by: Matteo Conti, et al.
Published: (2023-07-01)

Baseline Cytokine Profile Identifies a Favorable Outcome in a Subgroup of Colorectal Cancer Patients Treated with Regorafenib
by: Andrea Abbona, et al.
Published: (2023-02-01)

Combined quality and dose-volume histograms for assessing the predictive value of 99mTc-MAA SPECT/CT simulation for personalizing radioembolization treatment in liver metastatic colorectal cancer
by: Hugo Levillain, et al.
Published: (2020-12-01)

Cetuximab Can Be an Effective and Low-Toxicity Maintenance Treatment Drug in Patients With Metastatic Colorectal Cancer: A Real-World Study of Zhejiang Cancer Hospital
by: Meiqin Yuan, et al.
Published: (2021-05-01)

Using of multi-kinase inhibitor regorafenib for metastatic colorectal cancer
by: O I Kit, et al.
Published: (2017-06-01)

Thermosensitive Exosome–Liposome Hybrid Nanoparticle‐Mediated Chemoimmunotherapy for Improved Treatment of Metastatic Peritoneal Cancer
by: Qijun Lv, et al.
Published: (2020-09-01)

Cyclin D1 G870A Variant is Associated with Increased Risk of Microsatellite Instability-Positive Colorectal Cancer in Young Male Patients
by: Josifovski T, et al.
Published: (2007-01-01)

Concordance between microsatellite instability and mismatch repair protein expression in colorectal cancer and their clinicopathological characteristics: a retrospective analysis of 502 cases
by: Meihua Ye, et al.
Published: (2023-06-01)

Skin Toxicity as Predictor of Survival in Refractory Patients with <i>RAS</i> Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy
by: Davide Ciardiello, et al.
Published: (2021-11-01)

CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients
by: Stefania Napolitano, et al.
Published: (2022-06-01)

Primary Tumor Sidedness Predicts Bevacizumab Benefit in Metastatic Colorectal Cancer Patients
by: Xia-Hong You, et al.
Published: (2019-08-01)

Goblet Cell Carcinoid of Appendix
by: Kung-Chen Ho, et al.
Published: (2014-06-01)

Towards a molecular classification of colorectal cancer:The role of microsatellite instability status
by: Karl eHeinimann
Published: (2013-10-01)

The Role of Palliative Surgery for Malignant Bowel Obstruction and Perforation in Advanced Microsatellite Instability-High Colorectal Carcinoma in the Era of Immunotherapy: Case Report
by: Sean J. Judge, et al.
Published: (2020-04-01)

Microsatellite instability testing in colorectal cancer using the QiaXcel advanced platform
by: Isabel Förster, et al.
Published: (2018-04-01)

Hospitalizations and Clinical Outcome in Metastatic Colorectal Cancer During Regorafenib or TAS-102 Therapy
by: Florian Huemer, et al.
Published: (2020-09-01)

Translational analysis and final efficacy of the AVETUX trial – Avelumab, cetuximab and FOLFOX in metastatic colorectal cancer
by: Joseph Tintelnot, et al.
Published: (2022-12-01)

CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial
by: Yuankai Shi, et al.
Published: (2019-05-01)

Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer
by: Daisuke Kotani, et al.
Published: (2019-12-01)

Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet + Bevacizumab
by: Riccardo Giampieri, et al.
Published: (2021-09-01)